238764-22-2

Basic information

• Product Name: 6-FLUORO-CHROMAN-4-YLAMINE
• Synonyms: 6-FLUORO-CHROMAN-4-YLAMINE;6-fluorochroman-4-amine;2H-1-Benzopyran-4-amine, 6-fluoro-3,4-dihydro-;6-Fluoro-3,4-dihydro-2H-1-benzopyran-4-amine
• CAS NO: 238764-22-2
• Molecular Formula: C9H10FNO
• Molecular Weight: 167.18
• Mol File: 238764-22-2.mol

Chemical Properties

• Boiling Point: 230℃
• Flash Point: 93℃
• Appearance: /
• Density: 1.201
• Vapor Pressure: 0.068mmHg at 25°C
• Refractive Index: 1.539
• Storage Temp.: 2-8°C
• PKA: 9.12±0.20(Predicted)
• CAS DataBase Reference: 6-FLUORO-CHROMAN-4-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUORO-CHROMAN-4-YLAMINE(238764-22-2)
• EPA Substance Registry System: 6-FLUORO-CHROMAN-4-YLAMINE(238764-22-2)

Safety Data

• Hazardous Substances Data: 238764-22-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Fluoro-chroman-4-ylamine is used as a synthetic intermediate for the production of various drugs and active pharmaceutical ingredients. Its unique structural features, including the fluorine atom and amine group, contribute to the development of new therapeutic agents with improved pharmacological properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 6-fluoro-chroman-4-ylamine is employed as a valuable building block for the synthesis of novel organic molecules with bioactive properties. Its incorporation into molecular frameworks can lead to the discovery of new compounds with potential therapeutic applications.
Used in Drug Discovery Research:
6-Fluoro-chroman-4-ylamine plays a role in drug discovery research, where its unique structure and functional groups are explored for the design and synthesis of innovative drug candidates. 6-FLUORO-CHROMAN-4-YLAMINE can be a key component in the development of new chemical entities with specific biological targets, contributing to advancements in medicinal chemistry.

InChI:InChI=1/C9H10FNO/c10-6-1-2-9-7(5-6)8(11)3-4-12-9/h1-2,5,8H,3-4,11H2

Upstream product

• 199587-86-5 C₉H₈FNO₂ 
• 66892-34-0 6-fluoro-4-chromanone 
• 890839-05-1 6-fluoro-chroman-4-one O-methyl-oxime 

Relevant articles and documents

Selective Heteroaryl N-Oxidation of Amine-Containing Molecules

The first examples of nonenzymatic N-oxidation of heteroarenes in the presence of amines are reported. Pyridine, quinoline, and isoquinoline N-oxides are selectively formed in the presence of more reactive aliphatic and alicyclic amines by use of an in situ protonation strategy and an iminium salt organocatalyst. Application to late-stage functionalization that mimics phase 1 metabolism of small-molecule drugs is also demonstrated.

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors

A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a 2-benzimidazoylpurinone core structure is described. Through substitution of the benzimidazoyl moiety and optimization of the N-9 substituent of the purinone, compound 24 was identified incorporating a chroman-based functional group. Compound 24 shows excellent kinase activity, good oral bioavailability and demonstrates efficacy in an acute mechanistic mouse model through inhibition of interleukin-2 (IL-2) induced interferon-γ (INF-γ) production.

8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I:

7-Substituted Purine Derivatives for Immunosuppression

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III:

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.